Author Archives: F. Gòdia

Increase Viable Sf9 Cell Density and Baculovirus-Based VLP Production by Supplementation with Recombinant Insulin Human AF

by and

Virus-like particles (VLPs) have become a promising means for developing vaccines and gene therapies. Currently, vaccines based on VLPs are commercially available for human papillomavirus and hepatitis B and E. Other disease treatments with VLPs are undergoing clinical trials. Upon expression, the structural matrix polyprotein group-specific antigen (gag polyprotein) from the human immunodeficiency virus (HIV) has shown to accumulate beneath the lipidic membrane. After a sufficient number of gag polyproteins are recruited, the assembly process is finished, and the VLP…

August 4, 2019

Optimization of HEK 293 and CHO-S Cell Growth by Supplementation of Non-Animal Derived Components Using Design of Experiments (DoE)

by , , and

Mammalian cells are a widely used expression platform for the production of recombinant therapeutic proteins or viral particle-based vaccines since they typically perform appropriate protein post-translational modifications and authentic viral particle assembly. Of the available mammalian cells, CHO and HEK 293 are some of the most industrially relevant cell lines because they are cGMP compliant and are able to grow in suspension in a variety of serum-free media. Of note, production of human therapeutics in mammalian cell culture has become…

November 10, 2014